Bli medlem
Bli medlem

Du är här

2021-07-21

Sartorius Stedim Biotech SA: Information on Document Availability

Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability

21-Jul-2021 / 07:05 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

 

Aubagne, July 21, 2021

 

Information on Document Availability

The report on the first half 2021 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:

https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations

It contains the following information:

  • Business development for the period of January to June 2021 as well as the 2021 full year forecast for the Sartorius Stedim Biotech Group
  • Consolidated financial statements for the period ended June 30, 2021

 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.

 

Contact

Petra Kirchhoff       

Head of Corporate Communications    

+49 (0)551.308.1686      

petra.kirchhoff@sartorius.com    

 

 


Regulatory filing PDF file

File: Information on Document Availability




Language:English
Company:Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:+33 44 284 5600
E-mail:info@sartorius-stedim.com
Internet:www.sartorius-stedim.com
ISIN:FR0013154002
Euronext Ticker:DIM
AMF Category: Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report
EQS News ID:1220485
 
End of AnnouncementEQS News Service

1220485  21-Jul-2021 CET/CEST

Författare EQS Newswire

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.